Released Aug 7, 2023, before the open
10-Q filed Aug 7, 2023, 38 days after period end · 0001558370-23-013483
Q2 2023 · 10-Q
Revenue$35.08M$35.08M +300.7% vs Q2 2022+265.8% vs Q1 2023
Net Income$19.34M$19.34M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted$0.21$0.21 N/M vs Q2 2022N/M vs Q1 2023
Operating Income$20,421,000N/M
Operating Cash Flowderived$4,973,000N/M
Free Cash Flowderived$4,769,000N/M
Margins · derived
Operating margin58.2%+121.3 pt vs Q2 2022
Net margin55.1%+116.1 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $35.08M | $8.75M | $6.43M | $10.97M |
| Net Income | $19.34M | -$5.33M | -$11.24M | -$4.15M |
| EPS Diluted | $0.21 | -$0.11 | -$0.25 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR